Gray Susannah reported disposition to issuer involving 32,666 derivative units of Theravance Biopharma, Inc. on Sep 23, 2026

Disposition to issuer
Form 4 code D. Disposition of issuer equity securities to the issuer under Rule 16b-3(e).
Director
DIR
Filed Sep 24, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
—Shares × reported price
Shares traded
32,666Share Option (Right to Buy)
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Sep 23, 2026Disposition to issuer
Filed
Sep 24, 2026, 8:31 PM ET2-day reporting delay
Accession
0001833453-26-000009Code D · Transaction 229439
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 23, 2026Disposition to issuer42,137——Trade 229437
Sep 23, 2026Disposition to issuer6,009——Trade 229438
Sep 23, 2026Disposition to issuer22,044——Trade 229440
Sep 23, 2026Disposition to issuer23,576——Trade 229441
Sep 23, 2026Disposition to issuer24,258——Trade 229442
Sep 23, 2026Disposition to issuer13,398——Trade 229443
7 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

TBPH price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
TBPH · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 2, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −0.1%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time. F2: At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award. F3: At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.